KMS Pharma supports regulatory planning and dossier preparation for pharmaceutical products intended for selected international markets. Depending on the agreed scope, work may include assessing submission requirements, preparing or compiling dossier sections, coordinating technical information and helping organise responses to questions raised during review.
When comparing a Regulatory Affairs Company in India or a Dossier Development Company in India, consider how the team connects regulatory strategy with formulation, analytical, stability and other available product data. Requirements differ by product and jurisdiction, so the documentation plan should reflect the intended pathway and market.
Regulatory Dossier Preparation in India
Regulatory dossier preparation in India involves organising the scientific, technical and administrative information required for a pharmaceutical submission. The dossier should present product information clearly and consistently, with supporting evidence that matches the available source data and the requirements of the target market.
KMS Pharma supports dossier preparation and compilation based on the development information available and the programme's agreed scope. This may involve reviewing documentation, identifying information gaps, coordinating relevant technical contributors and structuring dossier sections for internal review and planned submission. The exact deliverables depend on the product, regulatory pathway and target jurisdiction.
Submission requirements
Identify target markets, applicable pathways and documentation needs before dossier work progresses.
Scientific dossier content
Prepare or compile relevant sections using the product data and source documents available.
Consistency and gap review
Check that dossier content aligns with source information and identify gaps that may require follow-up.
A well-organised dossier connects the regulatory pathway with clear, traceable product evidence.
Regulatory Affairs Company in India
Regulatory affairs helps connect pharmaceutical development activities with the requirements for a product's intended market. A regulatory plan may cover the proposed submission route, applicable guidance, required supporting data and the format in which information must be presented.
KMS Pharma supports regulatory planning and documentation coordination for pharmaceutical programmes. The work plan can be shaped around the development stage, product characteristics and target countries, with technical input from relevant contributors where required. Regulatory advice and submission scope should be confirmed against the current requirements for each product and jurisdiction.
Pathway assessment: Review the proposed route and target-market requirements for the product.
Evidence planning: Map available development information against expected dossier content.
Documentation coordination: Organise responsibilities, review stages and submission deliverables.
Dossier Development Company in India
A dossier may be developed alongside a product's development programme or compiled from existing information supplied by a partner. The suitable approach depends on the available data, the intended submission and the work required to make the documentation complete and consistent.
KMS Pharma supports dossier development planning and compilation based on agreed project requirements. This may involve coordinating product and development information, organising quality-related sections and documenting the evidence needed for the proposed submission. Missing information or additional study requirements should be identified rather than assumed to be available.
Dossier development
Build relevant documentation alongside product development and the generation of supporting evidence.
Dossier compilation
Organise existing partner or product data into the agreed structure and identify documentation gaps.
Source-aligned content
Keep written sections consistent with the underlying technical information and source records.
CTD Dossier Preparation in India
The Common Technical Document(CTD) in India provides a structured format for presenting information in many pharmaceutical regulatory submissions. Its modules organise administrative information, summaries and quality, nonclinical and clinical documentation as applicable to the product and pathway.
KMS Pharma can support planning and preparation of CTD dossier content according to the agreed scope and available source information. The required modules and level of detail depend on the submission type, product, target authority and relevant guidance. A document review can help identify missing sections, outdated information or inconsistencies that need to be addressed before submission.
Module structure: Organise the dossier according to the CTD structure applicable to the planned submission.
Quality information: Coordinate relevant product, manufacturing, control and stability documentation where included in scope.
Summary and supporting sections: Check consistency between summaries and the detailed evidence they describe.
eCTD Dossier in India
The electronic Common Technical Document (eCTD) is an electronic format used by certain regulatory authorities to organise and manage regulatory submission information. An eCTD submission involves more than converting documents to PDF; publishing requirements, document structure, lifecycle operations and technical validation criteria must be considered for the intended authority.
KMS Pharma can coordinate eCTD dossier preparation requirements within the agreed project scope, including organisation of dossier content and alignment with the target submission format. The applicable technical specifications and publishing responsibilities should be confirmed for the authority and submission type before work begins.
Electronic dossier organisation
Arrange content according to the required electronic submission structure and project scope.
Version and lifecycle awareness
Keep document versions and changes organised in line with the agreed submission workflow.
Technical requirements
Confirm publishing, validation and technical responsibilities for the relevant authority before submission.
ANDA Filing Support in India
An Abbreviated New Drug Application (ANDA) is a US FDA pathway used for qualifying generic drug products. An ANDA programme requires product-specific information and evidence, and its scope depends on the reference listed drug, dosage form, route of administration and applicable US requirements.
KMS Pharma can discuss ANDA filing support in India as part of regulatory dossier planning and documentation coordination. The work may involve organising available product and quality information, mapping dossier requirements and coordinating technical inputs within the agreed scope. Any product-specific requirements, testing needs and submission responsibilities should be assessed against current US FDA guidance.
Product and reference review: Establish the product details and relevant reference-product considerations.
Quality documentation: Identify the chemistry, manufacturing and controls information required for the programme.
Submission gap review: Review available documentation and identify outstanding items for technical follow-up.
ANDA eligibility and requirements are product-specific. Filing support does not guarantee acceptance, approval or a particular review timeline.
MHRA Marketing Authorisation in India
Pharmaceutical companies planning to supply generic medicines in the United Kingdom need to identify the appropriate marketing authorisation route and prepare documentation in line with the current requirements of the Medicines and Healthcare products Regulatory Agency (MHRA). The route and evidence depend on the product, its status and the intended application.
KMS Pharma supports planning for dossier documentation intended for international markets, including coordination of the information needed for a proposed UK submission. For MHRA marketing authorisation in India, the project scope should clarify the applicable route, dossier format, supporting quality information and any product-specific requirements. Current MHRA guidance and the relevant application procedure should be checked before submission planning is finalised.
Confirm the UK route
Identify the appropriate authorisation pathway and the requirements relevant to the product.
Map the required dossier
Review available documentation and identify the sections and evidence required for the application.
Coordinate submission preparation
Agree on documentation responsibilities, review stages and any outstanding information needed for the planned submission.
EU Dossier for Generic Medicines in India
Generic medicine submissions in the European Union must follow the applicable legal route and current European requirements. The dossier should provide the product and quality information required for the chosen procedure, with supporting evidence appropriate to the product and application.
KMS Pharma can support the preparation and organisation of documentation for an EU dossier for generic medicines in India, according to the agreed scope and available product data. The appropriate European procedure, documentation format and supporting requirements should be confirmed for the intended market and application before dossier preparation is completed.
Procedure assessment
Identify the intended EU procedure and check the documentation expectations for the application.
Product documentation
Organise relevant quality and development information in line with the agreed dossier plan.
Submission readiness
Review dossier consistency and flag missing information for resolution by the relevant technical team.
TGA Registration for Generic Medicines in India
Generic medicines intended for Australia are subject to the applicable requirements of the Therapeutic Goods Administration (TGA). The registration route and supporting documentation depend on the product, its characteristics and the relevant Australian regulatory pathway.
KMS Pharma can coordinate dossier planning for programmes considering TGA registration for generic medicines in India, based on the agreed scope and available evidence. The team should confirm the appropriate application route, dossier requirements, supporting quality information and any product-specific obligations against current TGA guidance before preparing a submission package.
Route and product review: Confirm the intended Australian pathway and relevant product characteristics.
Documentation mapping: Identify dossier sections and supporting evidence required for the planned application.
Quality and consistency review: Check the available dossier content against the agreed scope and current requirements.
CMC Regulatory Consultant in India
Chemistry, Manufacturing and Controls (CMC) information describes important aspects of a pharmaceutical product's composition, manufacture, testing, quality controls and stability. The details required in a regulatory submission depend on the dosage form, manufacturing process, development stage and target authority.
A CMC regulatory consultant in India may help teams organise quality information and identify where technical input is needed for dossier preparation. KMS Pharma can coordinate CMC-related documentation within the agreed scope, working with the relevant technical contributors and source data. The dossier should accurately reflect the actual product, process and supporting evidence rather than make assumptions about information that has not been generated.
Composition and development
Organise relevant formulation and product-development information provided for the programme.
Manufacturing information
Coordinate applicable manufacturing-process descriptions and supporting documentation.
Controls and stability
Structure available specifications, analytical information and stability evidence as required by the agreed dossier scope.
Deficiency Response Support in India
During regulatory review, an authority may issue questions or request additional information about a submitted dossier. A clear response should address the question directly, reference the relevant supporting evidence and remain consistent with the product information already submitted.
KMS Pharma can coordinate deficiency response support in India within the agreed project scope. This may include reviewing the request, identifying the relevant dossier sections, coordinating technical input and organising a documented response. If additional testing or new data is needed, the requirement and responsibility should be established with the relevant technical team.
Review the deficiency
Clarify what the authority has asked and identify the dossier sections affected.
Coordinate technical evidence
Obtain relevant source data and input from the contributors responsible for the information.
Prepare and check the response
Organise a clear, evidence-based answer and check consistency with the dossier and source documents.
Response acceptance and review timelines are determined by the relevant authority. Support with response preparation cannot guarantee a specific regulatory outcome.
Dossier Licensing and Out-Licensing in India
Dossier licensing and out-licensing can help pharmaceutical companies explore commercial partnerships for products or development assets. Before discussing a licensing arrangement, parties generally need a clear view of the product, available dossier documentation, intended markets, rights being offered and any remaining development or regulatory work.
KMS Pharma can discuss dossier-related requirements for licensing and out-licensing programmes as part of an agreed project scope. Documentation readiness, ownership, permitted use, territory, product status and data availability should be clarified by the parties and their legal and regulatory advisers. A dossier's availability does not by itself establish that it is suitable for every market or application.
Define the licensing scope: Clarify the product, rights, territories and intended commercial arrangement.
Review dossier status: Establish which documents and supporting data are available and whether updates are required.
Confirm market fit: Assess the intended market's requirements before treating existing documentation as submission-ready.
Ready Dossiers for Licensing in India
Companies evaluating ready dossiers for licensing in India should confirm the dossier's current status, product details, documentation scope and the markets for which the available information may be relevant. A dossier that exists for one jurisdiction or regulatory route may need additional work before it can support a different application.
KMS Pharma can discuss dossier preparation and licensing-related documentation requirements with interested pharmaceutical partners. Availability, ownership, licensing terms, data access and market-specific suitability must be verified for each opportunity. This page does not represent a live inventory or guarantee that a particular dossier is currently available for licensing.
Confirm dossier availability
Verify the specific product, dossier status, documentation scope and current availability directly.
Clarify licensing terms
Confirm ownership, territory, permitted use, data access and commercial terms with the relevant parties.
Review regulatory suitability
Determine whether the existing dossier fits the intended market or requires additional documentation or studies.
Choosing a Regulatory Dossier Preparation Partner in India
When selecting a regulatory partner, look for a clear explanation of the proposed scope, relevant market requirements, technical information needed and the responsibilities for preparing and reviewing each dossier section. A defined plan can help identify missing data and reduce avoidable confusion during document preparation.
Market-specific experience: Confirm familiarity with the submission pathway and current requirements relevant to your target markets.
Defined deliverables: Agree on dossier sections, document formats, review stages and submission responsibilities.
Technical coordination: Understand how CMC, analytical, stability and other technical inputs will be collected and checked.
Gap and deficiency support: Clarify how missing information and authority questions will be assessed and managed.
Transparent project scope: Confirm what is included, what depends on additional data and what falls outside the engagement.
The appropriate partner and work plan depend on the product, available evidence and target jurisdiction. Regulatory documentation should be reviewed against current requirements before submission.
Discuss your regulatory dossier requirements with KMS Pharma
Planning a pharmaceutical dossier for India or an international market? Contact KMS Pharma to discuss your product, target jurisdiction, available development data and the documentation or regulatory coordination your programme may require.
Start a Conversation